Loading...
Loading...
Apricus Biosciences, Inc.
APRI announced today that the
Japanese Patent Office has issued an official decision to allow Japanese
patent application entitled, "Crystalline Salts of Dodecyl
2-Propionate." The patent will cover compositions and
methods related to crystalline salts contained in the Company's NexACT^
permeation enhancer technology used in topical drug delivery. The salts
provide NexACT^ with an important range of physio-chemical characteristics
with various potential advantages versus other drug delivery technologies
including, improved compatability, water solubility and permeation
profiles. This patent, when issued, will provide Japanese patent protection to
May 2020, and will be the 15th patent granted for these salts worldwide with
four applications pending in this patent family.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in